Kuros Biosciences AG

Kuros Biosciences AG

  • Price (CHF)2.02
  • Today's Change0.00 / 0.00%
  • Shares traded3.37k
  • 1 Year change-8.18%
  • Beta1.2044
Data delayed at least 15 minutes, as of Jan 28 2022 16:31 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

  • Revenue in CHF (TTM)11.83m
  • Net income in CHF-5.78m
  • Incorporated1995
  • Employees51.00
  • Location
    Kuros Biosciences AGWagistrasse 25SCHLIEREN 8952SwitzerlandCHE
  • Phone+41 447334747
  • Fax+41 447334740
  • Websitehttp://www.kuros.ch/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Ebiquity plc67.02m-4.42m55.77m550.00--1.6030.180.8322-0.0429-0.04030.65140.35690.6686--2.2697,798.18-4.22-1.96-5.89-2.6153.4852.13-6.32-3.15--3.080.4863---16.54--48.31------
Deepverge PLC8.47m-5.27m56.97m9.00--1.81--6.73-0.0256-0.02560.04140.11760.33713.774.12---20.99-43.87-24.27-66.6643.7045.96-62.27-222.572.36-8.070.1056--444.71306.88-19.68--10.16--
Arribatec Group ASA-10.41bn-10.41bn57.82m349.00--1.69----------0.5617-----------34.47---45.93--76.82---95.51----0.1275--1,678.5799.08-76.91--19.29--
Exact Therapeutics AS0.00-6.03m59.30m8.00--4.20-----2.71-2.710.004.52------0.00--------------------0.0137-------123.18------
Renergetica SpA730.04k1.98m59.39m28.0029.935.4217.8881.350.23660.23660.0871.310.0266-0.35570.237125,591.647.66--11.53--826.35--287.97--1.473.370.5485---39.46--27.62------
Poltreg SA182.00k-398.13k63.44m----17.62--348.59-0.5292-0.52920.24213.39-----------------95.63---218.75--3.60--0.0199--40.00--9.20------
Kuros Biosciences AG11.83m-5.78m66.28m51.00--0.7798--5.60-0.2442-0.24420.69072.590.13573.1610.28257,173.90-6.63-19.70-6.90-20.8765.20---48.86-793.418.06--0.0275--57.7194.80-2.38------
Poolia AB175.83m5.22m67.17m4.31k16.064.898.820.3821.181.1841.643.873.38--4.64464,916.7010.044.4527.7413.91----2.971.24--180.280.149947.34-12.8914.08-70.12-14.994.373.71
System1 Group PLC31.22m3.36m68.16m146.0020.346.4719.962.180.2090.2091.970.6571.42--4.23187,014.9015.21--22.93--83.65--10.75----23.200.368---10.35--831.60------
Frontier IP Group Plc15.78m11.92m68.19m16.006.001.425.724.320.16580.16580.22010.69850.3901--17.78791,750.0029.4619.8329.6520.01----75.5165.15----0.000.0098.6544.23128.6353.2743.10--
Carillion plc5.50bn-1.33bn71.29m31.63k------0.013-2.49-2.499.74-1.011.1560.953.36139,493.50-27.663.40-60.046.407.939.31-24.103.490.71760.72031.7361.0011.241.14-6.48-1.6024.241.77
Dovre Group Oyj91.51m1.79m71.66m486.0039.212.6728.760.78310.01660.01660.85270.24451.65--3.82--2.991.105.541.7787.7399.791.810.6334--6.360.2326212.76-6.81-7.75-21.43---19.040.00
MagForce AG444.03k15.11m72.13m67.,688.2828.12-2.6864.77-4.334.0232.113,403.68-159.020.07435.280.2516---26.05-24.76268.91------
HydrogenPro AS2.54m-3.71m73.79m10.00--1.34--29.03-0.6175-0.61750.42389.130.0866----2,442,982.00-12.64---13.78--6.72---146.02------0.0045--5.57---24.05------
Generic Sweden AB (publ)10.57m1.68m74.17m17.0044.2228.5140.867.021.381.388.682.142.30134.437.326,272,765.0036.5112.6958.7517.8248.1955.4315.8810.452.3421,371.000.00131.1917.04-5.8523.1915.19-15.0221.67
MJ Hudson Group PLC49.62m-6.70m78.51m206.00--1.69--1.58-0.0316-0.03160.23390.21560.5227--3.08193,315.50-7.09---8.99--61.55---13.56-----38.980.3916--78.71--28.61------
Data as of Jan 28 2022. Currency figures normalised to Kuros Biosciences AG's reporting currency: Swiss Franc CHF

Institutional shareholders

19.70%Per cent of shares held by top holders
HolderShares% Held
Credit Suisse Asset Management (Schweiz) AGas of 02 Feb 20213.28m9.99%
Banque Pictet & Cie SAas of 31 Dec 20201.39m4.25%
Apo Asset Management GmbHas of 30 Nov 20211.31m3.98%
UBS Asset Management Switzerland AGas of 05 Jan 2022188.69k0.58%
Schroder Investment Management (Switzerland) AGas of 30 Nov 2018123.81k0.38%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 202070.55k0.22%
Migros Bank AGas of 30 Jun 202137.13k0.11%
Yorkville Advisors LLCas of 01 Dec 202029.52k0.09%
BlackRock Asset Management Schweiz AGas of 06 Jan 202221.62k0.07%
Lombard Odier Asset Management (Switzerland) SAas of 30 Sep 202116.84k0.05%
More ▼
Data from 30 Jun 2021 - 31 Dec 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.